The Atlanta Clinical & Translational Science Institute (ACTSI) would like to announce the continued support of the Emory Personalized Immunotherapy Center (EPIC) from the Samuel L. and Nancy W. Gordon Research Endowment. ACTSI began supporting the unique cellular therapy center in 2012. EPIC offers patients access to cutting-edge, innovative personalized cellular pharmaceuticals for treatment of human catastrophic illnesses arising from immune dysfunction by translating innovations in personalized cell therapy to first-in-human clinical trials.
The Samuel L. and Nancy W. Gordon Research Endowment will provide EPIC with $25,000 per year for three years for a total of $75,000 with the option of further ACTSI funding going forward. “EPIC very much appreciates the ACTSI and Gordon Endowment support and will put the funds to good use pioneering cellular therapies,” said Jacques Galipeau, MD FRCP(C), medical co-director, EPIC, professor of hematology and medical oncology and pediatrics, Emory University, and Georgia Research Alliance (GRA) Distinguished Cancer Scientist.
Over the years, ACTSI supported EPIC’s study to test an innovative first-in-human cellular therapy for inflammatory bowel disease (IBD) using mesenchymal stromal cells (MSCs) which have emerged as a novel approach for immune related disorders like IBD, as MSCs have been shown to have a broad spectrum of suppressive actions on both the innate and adaptive immune systems. This study used ACTSI’s Pediatric Clinical Research Unit at Egleston and partnered with Children's Healthcare of Atlanta. Read More
ACTSI is a city-wide partnership between Emory, Morehouse School of Medicine, and Georgia Institute of Technology and is one of over 60 in a national consortium striving to improve the way biomedical research is conducted across the country. The consortium, funded through the National Center for Advancing Translational Sciences (NCATS) and the National Institutes of Health’s Clinical and Translational Science Awards, shares a common vision to translate laboratory discoveries into treatments for patients, engage communities in clinical research efforts, and train the next generation of clinical investigators.
Atlanta Clinical & Translational Science Institute (ACTSI)-supported team, OculoStaple wins second place in the 2015 InVenture Prize at Georgia Tech. Team members Jackie Borinski, Mohamad Ali Najia, and Drew Padilla, all biomedical...